To the top

Page Manager: Webmaster
Last update: 4/19/2017 1:56 PM

Tell a friend about this page
Print version

Sverker Jern - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Sverker Jern


Sverker Jern

Postal Address: Su sahlgrenska, 41345 Göteborg
Visiting Address: Blå stråket 5 b wallenberglab/su , 41345 Göteborg

Department of Molecular and Clinical Medicine at Institute of Medicine (More Information)
SU Sahlgrenska
413 45 Göteborg
Fax: +46 31823762
Visiting Address: Blå stråket 5 B Wallenberglab/SU , 413 45 Göteborg

About Sverker Jern

Professor, Principal Investigator

Dr Sverker Jern is professor of Cardiovascular Physiology and senior consultant in Clinical Physiology at the Sahlgrenska University Hospital. Dr Jern’s research is focused on molecular mechanisms that regulate vascular hemostatic mechanisms in atherothrombotic conditions. His group has performed pioneering studies of the endogenous thromboprotective defense in blood vessels and current studies concern the key role of epigenetic mechanism in vascular fibrinolysis.

Dr Jern is an international authority in electrocardiography and has been director of Core ECG laboratories in several large-scale international cardiovascular intervention trials.

Main research

Our research is focused on atherothrombosis - mechanisms responsible for thrombotic vessel occlusions that cause myocardial infarction and ischemic stroke.

In early studies the group showed that in normal blood vessels the clinical outcome of a sudden intravascular clotting depends on whether the endogenous thromboprotective defense system can dissolve the clot before tissue damage occurs. In subsequent work it was found that some cardiovascular risk factors impair this function by suppressing the synthesis of the key fibrinolytic activator t-PA.

The group recently discovered that the main switch of this system is on the epigenetic level and involves histone modifications (acetylation) at critical points around the gene´s transcription start site. Since drugs are available that target this mechanism, current work is focused on the potential use of HDAC inhibitors as a novel clinical treatment to prevent atherothrombotic events. Research methods span from human and animal in vivo physiology to cellular and molecular biology including epigenetics.

Group Members

  • Helén Brogren, Postdoctoral Fellow
  • Mia Magnusson, PhD Student
  • Niklas Bergh, Postdoctoral Fellow
  • Pia Larsson, Postdoctoral Fellow
  • Thordis Hrafnkelsdottir, Research Fellow

Key Publications

Larsson P, Ulfhammer E, Magnusson M, Bergh N, Lunke S, El-Osta A, Medcalf RL, Svensson PA, Karlsson L, Jern S.
Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression.
PloS One. 7 e31573. (2012)

Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S.
Platelets retain high levels of active plasminogen activator inhibitor-1.
PloS One. 6 e26762. (2011)

Ulfhammer E, Larsson P, Karlsson L, Hrafnkelsdóttir T, Bokarewa M, Tarkowski A, Jern S.
TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent.
Journal of Thrombosis and Haemostasis. 4:1781-9. (2006)

Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S.
Platelets synthesize large amounts of active plasminogen activator inhibitor-1.
Blood. 104:3943-3948. (2004)

Hrafnkelsdóttir T, Wall U, Jern C, Jern S.
Impaired capacity for endogenous fibrinolysis in essential hypertension.
Lancet 352:1597-1598. (1998)

Latest publications

Showing 1 - 10 of 71





Showing 1 - 10 of 71

Page Manager: Webmaster|Last update: 4/19/2017

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?